PSG.DE Stock Holds €29 in Pre-Market, May 2026

PharmaSGP Holding SE (PSG.DE) trades at €29.0 on XETRA in pre-market activity on May 13, 2026. The German pharmaceutical company manufactures over-the-counter drugs and specialty healthcare products across Europe. PSG.DE stock shows resilience with a 51% gain over the past year and a market cap of €333.9 million. The company’s product portfolio includes Baldriparan for sleep disorders, RubaXX for rheumatic pain, and Neradin for sexual dysfunction. With 910 employees based in Gräfelfing, PharmaSGP continues to expand its European distribution network through pharmacies and wholesalers.

PSG.DE Stock Valuation and Technical Position

PSG.DE stock trades near its 50-day moving average of €28.52, showing stability in the current session. The stock sits €1.0 below its 52-week high of €30.0 and well above the €19.0 yearly low, reflecting strong recovery momentum. Volume today stands at 12,424 shares, representing a 2.3x increase over the average of 5,399 shares, indicating active pre-market interest.

Meyka AI rates PSG.DE stock with a grade of B+, suggesting a Buy recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating reflects the company’s solid fundamentals despite elevated valuation multiples. These grades are not guaranteed and we are not financial advisors.

Financial Metrics and Profitability Analysis

PSG.DE stock trades at a P/E ratio of 17.26, below the healthcare sector average of 28.48, making it relatively attractive on earnings. The company generates €5.52 in revenue per share with €0.89 in net income per share, demonstrating consistent profitability. Return on equity stands at 29.8%, significantly outperforming the sector average of 16.1%, showing efficient capital deployment.

The company maintains a current ratio of 2.68, indicating strong liquidity to cover short-term obligations. Operating margins reach 22.9%, while net profit margins hit 16.0%, both healthy for the specialty pharmaceutical industry. Free cash flow per share of €0.64 supports dividend payments and reinvestment. Track PSG.DE on Meyka for real-time updates on these key metrics.

Growth Trajectory and Market Sentiment

PSG.DE stock delivered 19.1% net income growth in the latest fiscal year, with 20.4% earnings per share growth, demonstrating accelerating profitability. Revenue expanded 17.5% year-over-year, driven by increased demand for pain management and sexual dysfunction treatments across European markets. The company’s three-year revenue growth per share reached 83.8%, reflecting sustained expansion.

Dividend per share jumped 180.3% in the latest period, signaling management confidence in cash generation. The stock’s 51% one-year return outpaced many healthcare peers, though elevated multiples suggest much of the upside is priced in. Meyka AI’s forecast model projects PSG.DE stock reaching €27.36 by year-end 2026, implying modest downside from current levels. Forecasts are model-based projections and not guarantees.

Market Sentiment and Trading Activity

Pre-market volume of 12,424 shares exceeds the 30-day average by 130%, suggesting institutional interest ahead of the regular session. The stock’s Keltner Channel middle band sits at €29.0, exactly where PSG.DE trades, indicating equilibrium between buyers and sellers. Average true range of €0.40 reflects low volatility, typical for specialty pharma stocks with stable cash flows.

The Money Flow Index at 50.0 shows neutral momentum, neither overbought nor oversold. Relative volume of 2.3x indicates above-average trading interest despite the early hour. Healthcare sector performance remains mixed, with the broader sector down 2.93% year-to-date, yet PSG.DE stock has outperformed significantly. This resilience reflects the company’s defensive business model and essential product portfolio.

Final Thoughts

PSG.DE stock demonstrates solid fundamentals with €29.0 pricing, B+ Meyka grade, and 29.8% return on equity that exceed sector averages. The German pharmaceutical company’s 17.5% revenue growth and 19.1% net income expansion support its valuation despite elevated multiples. With €2.54 cash per share and a 2.68 current ratio, PharmaSGP maintains financial flexibility for growth investments and shareholder returns. The 51% one-year gain reflects market recognition of the company’s niche strength in pain management and sexual health treatments. Investors should monitor earnings announcements scheduled for September 2025 and track sector dynamics, as healthcare…

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.